A Randomised, Open-Label, Phase III Study of Saruparib (AZD5305) Plus Camizestrant compared with Physician’s Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of Patients with BRCA1, BRCA2, or PALB2 Mutations and Hormone Receptor-Positive, HER2 Negative (IHC 0, 1+, 2+/ ISH non amplified) Advanced Breast Cancer (EvoPAR-Breast01)

• Código protocolo: D9722C00001 - EvoPAR-Breast01
• Código EudraCT: 2023-504180-16-00
• Servicio: Oncología
• Investigador/a principal:  Pimentel , Isabel
• Patología: Tumors
• Fase: Fase III